Findings

What do systematic reviews say?

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Zinc vs placebo

Mobility · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Quality of life · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Adverse effects of treatment · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ AZLI vs placebo

FEV1 % predicted: relative change from baseline · adults and children with CF

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 99 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Time to next exacerbation · adults and children with CF

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Participants hospitalised for respiratory exacerbation · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 0.88 [0.53, 1.45]
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Adverse events (AEs) (1 or more events) · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 1.08 [0.98, 1.19]
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

All‐cause mortality · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 5.41 [0.27, 109.87]
1 study · 100 participants
Moderate

Summary of findings: SLT A vs SLT B

Functional communication · adults with aphasia following stroke

Summary of findings: SLT A may leads to higher functional communication compared with SLT B (low certainty).

1 finding from 1 review

Speech and language therapy for aphasia following stroke 2016 · Cochrane Headline outcomes only
MD 11.75 [4.09, 19.4]
2 studies · 84 participants
Low

Summary of findings: SLT A vs SLT B

Severity of impairment · adults with aphasia following stroke

Summary of findings: SLT A probably leads to higher severity of impairment compared with SLT B (moderate certainty).

1 finding from 1 review

Speech and language therapy for aphasia following stroke 2016 · Cochrane Headline outcomes only
SMD 0.38 [0.07, 0.69]
5 studies · 187 participants
Moderate

Summary of findings: DHA‐P vs alternative ACTs

Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria

Summary of findings: DHA‐P probably leads to lower effective treatment of the blood stage parasite As assessed by:… compared with alternative ACTs (moderate certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 0.2 [0.08, 0.49]
3 studies · 334 participants
Moderate

Summary of findings: DHA‐P vs alternative ACTs

Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 · Adults and children with uncomplicated P. vivax malaria

Summary of findings: DHA‐P may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with alternative ACTs (low certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 0.21 [0.1, 0.46]
2 studies · 179 participants
Low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Change in FEV1 % predicted at end of antibiotic course: absolute post‐treatment values · adults and children with cystic fibrosis

Summary of findings: single showed no clear difference in change in FEV1 % predicted at end of antibiotic course: absolute… compared with combination intravenous anti‐pseudomonal antibiotic therapy (low certainty).

1 finding from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 5.25
2 studies · 93 participants
Low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Time to next course of antibiotics Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

2 findings from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Adverse events during treatment · adults and children with cystic fibrosis

The review found no eligible studies for this question.

2 findings from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 131 participants
Low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Quality of life · adults and children with cystic fibrosis

1 finding from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
GRADE not reported

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Change in sputum P aeruginosa density at end of treatment (cfu/g) · adults and children with cystic fibrosis

Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).

2 findings from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
Moderate
Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Need for extra treatment · adults and children with cystic fibrosis

The review found no eligible studies for this question.

2 findings from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found